RVVTF Revive Therapeutics Ltd

$RVVTF I warned him. Didn't I? So now we know that either a) big news is coming and the mm already blew his wad... Or The mm only had 1 mil-ish dark pool. Either way - I'm cooking

$RVVTF nerve agent literature keeps stressing that oximes alone cannot prevent long term brain injury. Multiple papers highlight that nerve agents trigger TBI like pathways including oxidative stress, neurovascular damage, BBB disruption, and loss of GABA(A) receptor function.These studies say future countermeasures must include CNS protective agents that stabilize oxidative and vascular injury beyond AChE reactivation.This is where bucillamine fits. Its dithiol structure delivers high capacity antioxidant cycling that addresses the ROS surge linked to TBI like injury it preserves hippocampal GABA(A) receptors which supports seizure control.RVV confirmed NAC caused pulmonary bleeding while bucillamine did not, giving it a major safety advantage.Bucillamine’s profile aligns with the neurovascular and TBI related mechanisms recent papers say are missing from current oxime based countermeasures.The direction is clear. Oximes need a CNS protective partner and bucillamine matches that need.

$RVVTF to our esteemed mm: It's been fun. Hope you never took my busting your balls personally. It was never intended that way! I want to apologize for continuously crushing your soul. I'll sell you back all my shares on the March up to $1+. Then I'm retired. For good. So as a show of good faith, let the price go up to .025. I'll behave. I promise. 😎

$RVVTF that mm must be getting wise. I SET THE FOOOR AT . 02 I'm reloading if he dips it. Hell - forgot Aquaman! I'll be the whole goddam Justice League if I'm pushed! Turning me in for a week ass matches trade for $60? That's gonna effing COST them! NFA. 👁️🍴🖍️🖍️ Good luck to everyone!

$RVVTF Aside from the formal December 9th milestone [cite: 25], any sudden momentum for $RVVTF usually hinges on a few specific operational catalysts dropping out of the blue: Official DRDC Study Results: Formal updates or final data releases regarding the Defence R&D Canada bucillamine nerve-agent countermeasure evaluations [cite: 1.1.2]—especially anything expanding on safety or CNS/GABA protection advantages over standard oximes. Partnership or Grant Announcements: Given the wider push for government defense contracts in this space (similar to recent sector deals like Kindeva's $226M autoinjector contract [cite: 20]), any non-dilutive funding, government partnership, or licensing agreement update would act as an immediate catalyst. Filing Drops / Share Structure Clarity: Updates on the private placement tranches [cite: 1.1.1] or official notices ahead of the shareholder meeting regarding call-in details [cite: 25].

$RVVTF DRDC Study Updates: Final authorizations and deeper findings regarding the Defence R&D Canada (DRDC) bucillamine nerve-agent countermeasures study remain on the radar, especially following earlier preclinical safety data comparing it to NAC [cite: 38]. December 9th Shareholder Meeting: Discussions center around whether management will open the meeting for live shareholder call-ins and whether any strategic updates or partnership developments will be unveiled [cite: 25]

$RVVTF Opinion regarding the forthcoming shareholders meeting on December 9th: If MFrank opens the meeting allowing shareholders to call in & listen vs shutting us out like last year -- I think they'll be good news announced at this meeting...

$RVVTF Bottom Line from the Ai Analysis (page 3 of my post) - pretty darn bullish if you ask me - so far so good with DRDC studies! The Practical Outlook If Bucillamine completes successful clinical trials for biodefense, it will likely be incorporated into the standard Chemical, Biological, Radiological, and Nuclear (CBRN) protocol alongside standard countermeasures. In this framework, a soldier or patient would receive an immediate ATNAA administration to survive the initial exposure, followed by Bucillamine to preserve brain and lung functionality against the long-term cellular trauma and inflammation that nerve agents leave behind.

$RVVTF Ask moving up a bit. I wonder what this might do if we get a significant update this month??

$RVVTF What is the absolute deadline for RVVTF to update their financials on the Otcmarkets? Is it October 2026? Isn't RVVTF current on the Canadian side? What is taking so long??

$RVVTF It has no approved indication, you can’t sell anything that has no clinical human value or benefit whatsoever- its like trying to build a house with no foundation.

$RVVTF I saw the Kendeva Post about the $266 Million contract and had to look into what they had vs Buci - I put it through Google Ai - and shared the answer. I like that Buci - even though not a replacement is being looked at as an add on to ATNAA - gold standard - to help protect against down stream effects - different biological pathways - so not a competitive product - but rather a complimentary product - breathed a sigh of relief - because that's a much tougher mountain to scale if Buci were going head to head with the gold standard

$RVVTF Bucillamine is not an alternative to ATNAA, but rather a potential future "add-on" therapeutic. While ATNAA is an established, regulatory-approved tactical antidote that actively halts a life-threatening acute cholinergic crisis, Bucillamine is an experimental medical countermeasure currently being researched to protect the brain and lungs from downstream tissue damage caused by exposure. They operate on completely different biological pathways, which are compared below: Feature ATNAA (Atropine + Pralidoxime Chloride) Bucillamine (Experimental) Status Approved gold-standard treatment deployed globally by military and emergency services. Experimental countermeasure undergoing animal model research (e.g., via DRDC) Primary Mechanism Antagonizes acetylcholine receptors (Atropine) and reactivates the acetylcholinesterase enzyme (Pralidoxime). Thiol donor/Antioxidant that replenishes intracellular glutathione to fight severe oxidative stress and inflammation. continued...